Late Onset Ventilator-Associated Pneumonia Due to Multidrug-Resistant Acinetobacter spp.: Experience with Tigecycline

被引:42
作者
Curcio, D. [1 ]
Fernandez, F. [1 ]
Vergara, J. [3 ]
Vazquez, W. [2 ]
Luna, C. M. [4 ]
机构
[1] Infectol Inst SRL, Buenos Aires, DF, Argentina
[2] Hosp Espanol Mendoza, Mendoza, Argentina
[3] Hosp Ramos Mejia, Buenos Aires, DF, Argentina
[4] Hosp Clin Jos de San Martin, Buenos Aires, DF, Argentina
关键词
Acinetobacter spp; ventilator-associated pneumonia; tigecycline; INTENSIVE-CARE-UNIT; MORTALITY PROBABILITY-MODELS; IN-VITRO ACTIVITIES; BAUMANNII; COLISTIN;
D O I
10.1179/joc.2009.21.1.58
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The aim of the study was to evaluate the clinical success rate of 73 patients with ventilator-associated pneumonia (VAP) caused by multidrug-resistant (MDR)-Acinetobacter spp. treated with tigecycline in seven Intensive Care Units in Argentina and to determine which predictor variables were significant in this context. Clinical success in our patients was 69.86% (Cl= 58.65-81.07%) 51/73, without significant differences between patients with VAP due to MDR-Acinetobacter spp. carbapenem-susceptible or carbapenem-resistant and only susceptible to colistin, minocyline and tigecycline (70% 44/73 vs. 69% 29/73 respectively, p=0.9006), and between patients who received 48h of prior antibiotics (including those who did not receive any) and those who received >48h of prior antibiotics (73.3% 22/30 vs 67.4% 29/43 respectively, p=0.7791). Age >67 and using other method than BAL for respiratory sampling were identified as predicting variables for negative clinical outcome. Our results suggest that tigecycline may be an acceptable alternative for therapy in patients with VAP caused by MDR-Acinetobacter spp. Nevertheless, only controlled clinical trials will provide the evidence to support approval for new indications.
引用
收藏
页码:58 / 62
页数:5
相关论文
共 14 条
[1]  
Bantar C, 2000, Int J Infect Dis, V4, P85
[2]  
BERGOGNEBEREZIN E, 1996, CLIN MICROBIOL REV, V344, P1329
[3]  
Clinical and Laboratory Standards Institute, 2007, M100S17 CLSI
[4]   Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline [J].
Conte, JE ;
Golden, JA ;
Kelly, MG ;
Zurlinden, E .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2005, 25 (06) :523-529
[5]  
Curcio D, 2007, REV CHIL INFECTOL, V24, P497, DOI /S0716-10182007000600012
[6]   The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient [J].
Heyland, DK ;
Cook, DJ ;
Griffith, L ;
Keenan, SP ;
Brun-Buisson, C .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 159 (04) :1249-1256
[7]   MORTALITY PROBABILITY-MODELS (MPM-II) BASED ON AN INTERNATIONAL COHORT OF INTENSIVE-CARE UNIT PATIENTS [J].
LEMESHOW, S ;
TERES, D ;
KLAR, J ;
AVRUNIN, JS ;
GEHLBACH, SH ;
RAPOPORT, J .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 270 (20) :2478-2486
[8]   Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections [J].
Li, Jian ;
Nation, Roger L. ;
Turnidge, John D. ;
Milne, Robert W. ;
Coulthard, Kingsley ;
Rayner, Craig R. ;
Paterson, David L. .
LANCET INFECTIOUS DISEASES, 2006, 6 (09) :589-601
[9]   Tigecycline [J].
Pankey, GA .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2005, 56 (03) :470-480
[10]   Emergence of PER-2 and VEB-1a in Acinetobacter baumannii strains in the Americas [J].
Pasteran, Fernando ;
Rapoport, Melina ;
Petroni, Alejandro ;
Faccone, Diego ;
Corso, Alejandra ;
Galas, Marcelo ;
Vazquez, Miryam ;
Procopio, Adriana ;
Tokumoto, Marta ;
Cagnoni, Viviana .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (09) :3222-3224